Louisa Jordison

Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom.

Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023.